ArticleSmart molecules : open access2026
A photoimmune synergizing RNA interference technology for highly effective antitumor treatment.
Article in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photoimmunotherapy and RNA interference (RNAi) hold great potential for tumor therapy but exhibit limited efficacy as monotherapies. In this work, we report a red-light-activated combinatorial therapy that integrates photodynamic immunotherapy (PIT) with RNAi via a rationally designed photosensitizer, FNBS, developed on the basis of our previously reported advanced photosensitizer platform, HNBS. Upon cellular uptake and following red light irradiation, FNBS induces pyroptosis through the activation of nucleotide-binding oligomerization domain-like receptor thermal protein domain associated protein 3 inflammasome pathways, thereby enhancing antitumor immune responses and converting "cold" tumors into "hot" tumors. Meanwhile, ROS-mediated oxidation of the furan moiety enables covalent RNA crosslinking and subsequent RNA degradation, thereby facilitating targeted RNAi. Owing to this dual mechanism, effective cancer cell elimination is achieved under normoxic (21% O
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.